Loading…
← CockpitCompetitor Analysis › SN..L Smith & Nephew plcOpen in the cockpit ↗

Smith & Nephew plcSN..LCompetitor analysis, valuation and peers

United Kingdom · GBP·Health Care›Medical Specialties

UK medical-device maker producing orthopedic implants (hips/knees), sports medicine and advanced wound-care products.

≈ A UK medtech peer to Stryker or Zimmer Biomet, but smallerMomentum strong 60
Mkt cap
$12.6B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$61.4M
20-day average traded
Fwd P/E
14.2×
forward earnings
ROIC−WACC
-0.5 pp
WACC 10.2%
Hurdle
+6 pp
Req g minus delivered
Official | Implied
BBB+ / BBB
agencies · bond market
Next earnings
103 days
1 Mar 2027
Close · GBP£1,148
1D-0.4%
1W-0.7%
1M+5.5%
3M+6.9%
6M+0.8%
YTD-7.3%
1Y-7.3%
ATR %2.4%
52w lowhigh17.8% off high

What Smith & Nephew does

UK medical-device maker producing orthopedic implants (hips/knees), sports medicine and advanced wound-care products.

Sells implants and surgical instruments to hospitals, which usually receive instrument sets on loan alongside the implants, and wound-care dressings and devices to health systems. Orthopedics is the largest of its three businesses and the US the biggest market. The shares are also listed as ADRs in New York.

In one line: A UK medtech peer to Stryker or Zimmer Biomet, but smaller.

Products and services

  • Orthopedic reconstruction (hip/knee implants)
  • Sports medicine/ENT
  • Advanced wound management

Customers

  • Orthopedic surgeons
  • Hospitals
  • Wound-care clinicians

Where it sits in the supply chain

  • Health care
  • Medical devices
  • Orthopedics, sports medicine, wound…

What could go right

  • Aging population/joint-replacement volume growth
  • Robotics-assisted surgery adoption

What could go wrong

  • Pricing pressure from hospital group purchasing
  • Market-share loss to larger orthopedics rivals

Moat: narrow (switching costs, customer qualification, IP). Surgeon training and preference for implant systems and instrument sets create switching costs once adopted.

Headquarters: London, UK · Founded: 1856 · Employees: 18,362

Named competitors

Smith & Nephew at a glance

Size Smith & Nephew (SN..L) is a United Kingdom Health Care company (Medical Specialties) with a market value of $12.6B, the 45th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £1,148 on 18 Nov 2026.

Performance Over six months the shares gained 0.8%, against +25.3% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +6.2%); the operating margin is 17.1% (peer median 15.8%).

Valuation It trades at 14.2× forward earnings against a peer median of 20.1× (6th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points below its cost of capital (10.2% WACC).

Credit Smith & Nephew has 2 bonds outstanding ($1.11B), rated BBB+ by the agencies and trading like BBB at a weighted spread of 106 bp.

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 124SN..L 101
Six months, rebased to 100: Smith & Nephew against the median of its 20 peers (local-currency closes).

Smith & Nephew financials

Reported figures in GBP; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue£4.69B£4.68B£4.55B£4.46B£4.23B
Revenue growth—+3%+2%+5%—
Gross profit£3.20B£3.13B£3.02B£2.98B£2.82B
EBITDA£1.25B£1.24B£1.20B£1.18B£1.08B
Net income£473M£474M£322M£212M£181M
Free cash flow£631M£646M£474M£146M£90.1M
Capital expenditure£357M£329M£298M£344M£291M
Total debtn/a£2.47B£2.65B£2.42B£2.39B

Quarterly statements and history in the cockpit →

Smith & Nephew competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%PEN7733BAXBIMLENSKARTALGNCOOGKOS688271AVTRDEMANTQGENBIOPODDBRKRCOLO-BRVTYGMEDZBH7701SN..L6-month return →1-month return →
Up and to the right = strong over both horizons. Smith & Nephew is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×PEN7733BAXBIMLENSKARTALGNGKOS688271DEMANTQGENBIOPODDBRKRGMEDSN..LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Smith & Nephew is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PEN7733BAXBIMLENSKARTALGNCOOAVTRDEMANTQGENBIOPODDBRKRCOLO-BRVTYGMEDSN..LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Smith & Nephew is the large dot.

Smith & Nephew competitors and peer comparison

Head to head with its named competitors (SN..L vs SYK vs ZBH vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
ConvaTec CTEC.L$6.78B+37%+2%16%17.7×17.2%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Smith & Nephew compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Smith & Nephew against its 20 peers (data as of 18 Nov 2026)
MeasureSN..LPeer medianRank in peer set
1-month return+5.5%+4.2%9th highest of 21
6-month return+0.8%+25.3%6th lowest of 21
Distance from 52-week high-17.8%-12.4%8th lowest of 21
Revenue growth (TTM)+2.2%+6.2%6th lowest of 21
Operating margin17.1%15.8%9th highest of 21
Forward P/E14.2×20.1×6th cheapest of 21
Growth the price implies (Req g, 7 yrs)11.1%10.0%9th most demanding of 19
Growth delivered (Del g)+5.6%+7.8%8th lowest of 19
Hurdle (Req g minus delivered)+5.5 pp+3.7 pp9th most demanding of 19
ROIC minus cost of capital-0.5 pp+2.3 pp10th lowest of 21
EV / EBITDA9.5×13.4×3rd cheapest of 19
Net debt / EBITDA1.8×0.9×8th most indebted of 19
Bond spread106 bp108 bp4th tightest of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%

Smith & Nephew bonds and credit

Smith & Nephew has 2 bonds outstanding with $1.11B face value. The agencies rate it BBB+; its bonds trade like BBB. Weighted yield 4.29%, a spread of 106 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Smith & Nephew's main competitors?
Named competitors: Stryker (SYK), Zimmer Biomet (ZBH), Johnson & Johnson MedTech (JNJ), ConvaTec Group (CTEC.L), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Penumbra (PEN), Olympus (7733.T), Baxter International (BAX), bioMerieux (BIM.PA), Lenskart Solutions (LENSKART.NS), Align Technology (ALGN).
Is Smith & Nephew expensive compared with its peers?
On forward p/e it trades at 14.2× against a peer median of 20.1×, 6th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Smith & Nephew stock performed?
Over six months to 18 Nov 2026 the shares returned +0.8% against +25.3% for the median peer; over one year -7.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.